Journal Article

The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK

Gordon, Melita A., Levine, Myron M., Kotloff, Karen L., Luby, Stephen P., Zaidi, Anita, Date, Kashmira, Qadri, Firdausi, Mohan, Vadrevu Krishna, Meiring, James E., Hombach, Joachim, Clemens, John, Darton, Thomas C., Mulholland, Kim, Basnyat, Buddha, Dougan, Gordon, Garrett, Denise, Bentsi-Enchill, Adwoa D., Pollard, Andrew J., Neuzil, Kathleen, Salisbury, David, Pitzer, Virginia E., Heyderman, Robert S., Gibani, Malick, Marfin, Anthony A., Gessner, Bradford D.

2017

Overview

Typhoid fever is estimated to cause between 11.9–26.9 million infections globally each year with 129,000–216,510 deaths. Access to improved water sources have reduced disease incidence in parts of the world but the use of efficacious vaccines is seen as an important public health tool for countries with a high disease burden. A new generation of Vi typhoid conjugate vaccines (TCVs), licensed for use in young children and expected to provide longer lasting protection than previous vaccines, are now available. The WHO Strategic Advisory Group of Experts on Immunization (SAGE) has convened a working group to review the evidence on TCVs and produce an updated WHO position paper for all typhoid vaccines in 2018 that will inform Gavi, the Vaccine Alliance's future vaccine investment strategies for TCVs. The Typhoid Vaccine Acceleration Consortium (TyVAC) has been formed through a $36.9 million funding program from the Bill & Melinda Gates Foundation to accelerate the introduction of TCVs into Gavi-eligible countries. In October 2016, a meeting was held to initiate planning of TCV effectiveness studies that will provide the data required by policy makers and stakeholders to support decisions on TCV use in countries with a high typhoid burden. Discussion topics included (1) the latest evidence and data gaps in typhoid epidemiology; (2) WHO and Gavi methods and data requirements; (3) data on TCV efficacy; (4) cost effectiveness analysis for TCVs from mathematical models; (5) TCV delivery and effectiveness study design. Specifically, participants were asked to comment on study design in 3 sites for which population-based typhoid surveillance is underway. The conclusion of the meeting was that country-level decision making would best be informed by the respective selected sites in Africa and Asia vaccinating children aged from 9-months to 15-years-old, employing either an individual or cluster randomized design with design influenced by population characteristics, transmission dynamics, and statistical considerations.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Africa / Age / Asia / Charities / Children / Clinical decision making / Clinical trials / Clinical Trials as Topic / Congresses as Topic / Conjugates / Consortia / Cost effectiveness / Decision making / Design / Disease / disease incidence / Ebola virus / Effectiveness / Effectiveness studies / Epidemiology / experimental design / experts / Fever / funding / Global health / Hepatitis / Humans / Immunization / Investment strategy / issues and policy / Licenses / Low income groups / Mathematical models / monitoring / Mortality / planning / Pneumonia / Policy / Population (statistical) / Population characteristics / Public health / stakeholders / Tetanus / Typhoid / typhoid fever / Typhoid Fever - immunology / Typhoid Fever - prevention & control / Typhoid-Paratyphoid Vaccines - immunology / Typhoid-Paratyphoid Vaccines - therapeutic use / United Kingdom / Vaccine efficacy / Vaccines / Vaccines, Conjugate - immunology / Vaccines, Conjugate - therapeutic use / Waterborne diseases / Working groups / World Health Organization